These findings led to FDA approvals for PD-L1 IHC assays, such as the Dako PD-L1 IHC 28-8 PharmDx test as a supplementary diagnosis for patients with metastatic melanoma who may be treated with nivolumab (anti-PD-1). This evidence concerns the gene CD274 and metastatic melanoma.